chr17:38171693:> Detail (hg19)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr17:38,171,693-38,174,066 |
hg38 | chr17:40,015,440-40,017,813 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.004 | squamous cell carcinoma | NA | BeFree,LHGDN | Detail | |
0.120 | Carcinoma, Transitional Cell | NA | CTD_human | Detail | |
0.120 | Cardiomyopathy, Dilated | NA | CTD_human | Detail | |
<0.001 | CNS disorder | NA | BeFree | Detail | |
<0.001 | Chest Pain | NA | BeFree | Detail | |
0.002 | chorioamnionitis | NA | GAD | Detail | |
<0.001 | choriocarcinoma | NA | BeFree | Detail | |
0.001 | Congenital chromosomal disease | NA | BeFree | Detail | |
0.001 | colitis | NA | BeFree | Detail | |
<0.001 | Colonic Neoplasms | NA | BeFree | Detail | |
<0.001 | Coronary Arteriosclerosis | NA | BeFree | Detail | |
<0.001 | Coronary heart disease | NA | BeFree | Detail | |
0.080 | cystitis | NA | RGD | Detail | |
<0.001 | Cyst | NA | BeFree | Detail | |
<0.001 | Cytomegalovirus Infections | NA | BeFree | Detail | |
0.120 | depressive disorder | NA | CTD_human | Detail | |
<0.001 | dermatitis | These JunB-deficient mutant mice display several phenotypes from skin inflammati... | BeFree | 26458100 | Detail |
0.120 | diarrhea | NA | CTD_human | Detail | |
<0.001 | diphtheria | NA | BeFree | Detail | |
<0.001 | Empyema | NA | BeFree | Detail | |
<0.001 | Experimental Autoimmune Encephalomyelitis | NA | BeFree | Detail | |
<0.001 | Enterocolitis | NA | BeFree | Detail | |
<0.001 | Eosinophilia | NA | BeFree | Detail | |
0.120 | Esophageal Neoplasms | NA | BeFree,CTD_human | Detail | |
<0.001 | Fanconi anemia | NA | BeFree | Detail | |
<0.001 | Fatigue | NA | BeFree | Detail | |
<0.001 | Fatty Liver | Granulocyte-colony stimulating factor prevents the development of hepatic steato... | BeFree | 25671834 | Detail |
0.002 | Fetal Membranes, Premature Rupture | NA | GAD | Detail | |
0.120 | Fever | NA | CTD_human | Detail | |
0.120 | Fibrosis | NA | CTD_human | Detail | |
0.120 | Gastrointestinal Diseases | NA | CTD_human | Detail | |
<0.001 | glioblastoma | NA | BeFree | Detail | |
<0.001 | Glioma | NA | BeFree | Detail | |
<0.001 | Glycogen Storage Disease Type I | NA | BeFree | Detail | |
0.002 | Graft-vs-Host Disease | NA | BeFree | Detail | |
<0.001 | chronic granulomatous disease | NA | BeFree | Detail | |
0.120 | Head and Neck Neoplasms | NA | CTD_human | Detail | |
0.120 | Headache | NA | CTD_human | Detail | |
0.120 | Heart Diseases | NA | CTD_human | Detail | |
0.120 | Heart failure | NA | BeFree,CTD_human | Detail | |
<0.001 | congestive heart failure | NA | BeFree | Detail | |
0.120 | Hemangiosarcoma | NA | CTD_human | Detail | |
<0.001 | Hematological Disease | NA | BeFree | Detail | |
<0.001 | Hemoglobinopathies | NA | BeFree | Detail | |
0.120 | hepatic veno-occlusive disease | NA | CTD_human | Detail | |
<0.001 | hepatitis | NA | BeFree | Detail | |
<0.001 | hepatitis A | NA | BeFree | Detail | |
<0.001 | hepatitis B | NA | BeFree | Detail | |
<0.001 | hepatitis C | NA | BeFree | Detail | |
0.002 | HIV Infections | NA | BeFree | Detail | |
0.120 | Hodgkin Disease | NA | CTD_human | Detail | |
0.120 | Hyperbilirubinemia | NA | CTD_human | Detail | |
<0.001 | pulmonary hypertension | The synergistic therapeutic effect of hepatocyte growth factor and granulocyte c... | BeFree | 23933910 | Detail |
<0.001 | Immunologic Deficiency Syndromes | NA | BeFree | Detail | |
0.120 | Infarction | NA | CTD_human | Detail | |
<0.001 | Inflammatory Bowel Diseases | NA | BeFree | Detail | |
<0.001 | ischemia | NA | BeFree | Detail | |
0.120 | Kidney Diseases | NA | CTD_human | Detail | |
0.002 | Premature Obstetric Labor | NA | GAD | Detail | |
0.120 | leiomyosarcoma | NA | CTD_human | Detail | |
0.007 | leukemia | NA | BeFree | Detail | |
0.001 | chronic lymphocytic leukemia | Angiogenic factors such as leptin, granulocyte colony-stimulating factor (G-CSF)... | BeFree | 25459668 | Detail |
<0.001 | hairy cell leukemia | NA | BeFree | Detail | |
<0.001 | lymphoid leukemia | NA | BeFree | Detail | |
0.002 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
<0.001 | Leukemia, Lymphocytic, Acute, L1 | NA | BeFree | Detail | |
0.140 | Leukemia, Myelocytic, Acute | Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (... | BeFree,CTD_human | 24488798 | Detail |
0.140 | Leukemia, Myelocytic, Acute | Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in com... | BeFree,CTD_human | 24623261 | Detail |
0.140 | Leukemia, Myelocytic, Acute | Low-dose homoharringtonine and cytarabine in combination with granulocyte colony... | BeFree,CTD_human | 24724783 | Detail |
0.140 | Leukemia, Myelocytic, Acute | G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatme... | BeFree,CTD_human | 25545153 | Detail |
0.002 | myeloid leukemia | NA | BeFree | Detail | |
0.010 | Myeloid Leukemia, Chronic | NA | BeFree,GAD | Detail | |
<0.001 | Leukemia, Myeloid, Chronic-Phase | NA | BeFree | Detail | |
<0.001 | acute myelomonocytic leukemia | NA | BeFree | Detail | |
<0.001 | chronic neutrophilic leukemia | NA | BeFree | Detail | |
0.006 | acute promyelocytic leukemia | In this study, we report the development of t-acute promyelocytic leukemia in a ... | BeFree | 25892894 | Detail |
0.132 | leukopenia | Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplemen... | BeFree,CTD_human | 25469044 | Detail |
0.132 | leukopenia | Due to the severe neutropenia the patient had developed nosocomial sepsis and th... | BeFree,CTD_human | 25804016 | Detail |
<0.001 | liver cirrhosis | NA | BeFree | Detail | |
0.120 | Liver Cirrhosis, Experimental | NA | CTD_human | Detail | |
0.120 | Liver diseases | NA | CTD_human | Detail | |
0.121 | Liver neoplasms | NA | BeFree,CTD_human | Detail | |
0.080 | Lung diseases | NA | RGD | Detail | |
0.005 | Chronic Obstructive Airway Disease | NA | BeFree,GAD | Detail | |
0.003 | Lung Neoplasms | NA | LHGDN | Detail | |
0.002 | lymphoma | NA | BeFree | Detail | |
0.120 | Lymphoma, Non-Hodgkin | NA | BeFree,CTD_human | Detail | |
<0.001 | Malignant neoplasm of stomach | NA | BeFree | Detail | |
0.121 | melanoma | We hypothesized that expression of CD114, the cell surface receptor for granuloc... | BeFree,CTD_human | 26124323 | Detail |
<0.001 | meningioma | NA | BeFree | Detail | |
0.002 | Monosomy | NA | BeFree | Detail | |
<0.001 | Mucocutaneous Lymph Node Syndrome | NA | BeFree | Detail | |
0.121 | multiple myeloma | We aimed to assess the efficacy of vinorelbine plus granulocyte colony-stimulati... | BeFree,CTD_human | 25278456 | Detail |
<0.001 | multiple sclerosis | In conclusion, our data strongly indicate that G-CSF-induced CXCR2 expression is... | BeFree | 25697397 | Detail |
0.120 | myopathy | NA | CTD_human | Detail | |
<0.001 | Myelodysplasia | NA | BeFree | Detail | |
<0.001 | myelofibrosis | NA | BeFree | Detail | |
<0.001 | Myelomonocytic leukemia | NA | BeFree | Detail | |
<0.001 | Myeloproliferative disease | G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatme... | BeFree | 25545153 | Detail |
0.004 | myocardial infarction | NA | BeFree,LHGDN | Detail | |
<0.001 | narcolepsy | Increased plasma IL-6, IL-8, TNF-alpha, and G-CSF in Japanese narcolepsy. | BeFree | 24994458 | Detail |
0.121 | Neoplasm Metastasis | NA | BeFree,CTD_human | Detail | |
0.002 | Pathologic Neovascularization | NA | GAD | Detail | |
<0.001 | nephroblastoma | NA | BeFree | Detail | |
0.120 | nervous system disorder | NA | CTD_human | Detail | |
<0.001 | neuroblastoma | NA | BeFree | Detail | |
0.135 | neutropenia | Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplemen... | BeFree,CTD_human,LHGDN | 25469044 | Detail |
0.135 | neutropenia | Due to the severe neutropenia the patient had developed nosocomial sepsis and th... | BeFree,CTD_human,LHGDN | 25804016 | Detail |
<0.001 | obesity | NA | BeFree | Detail | |
<0.001 | osteoporosis | NA | BeFree | Detail | |
<0.001 | osteosarcoma | NA | BeFree | Detail | |
<0.001 | ovarian carcinoma | NA | BeFree | Detail | |
0.120 | Pain | NA | BeFree,CTD_human | Detail | |
0.120 | pancytopenia | NA | BeFree,CTD_human | Detail | |
<0.001 | periodontitis | However, the roles of other genes, such as CSF3 (colony stimulating factor 3 rec... | BeFree | 24476546 | Detail |
0.120 | Peripheral neuropathy | NA | CTD_human | Detail | |
<0.001 | platelet storage pool deficiency | NA | BeFree | Detail | |
<0.001 | polycythemia vera | NA | BeFree | Detail | |
0.002 | pre-eclampsia | NA | GAD | Detail | |
<0.001 | Precancerous Conditions | NA | BeFree | Detail | |
0.002 | Preleukemia | G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatme... | BeFree | 25545153 | Detail |
<0.001 | psoriasis | NA | BeFree | Detail | |
0.120 | pulmonary fibrosis | NA | CTD_human | Detail | |
<0.001 | Respiration Disorders | IL-8 and G-CSF play major roles in neutrophil activation in respiratory diseases... | BeFree | 24994458 | Detail |
0.002 | Respiratory Syncytial Virus Infections | NA | GAD | Detail | |
<0.001 | Respiratory Tract Diseases | IL-8 and G-CSF play major roles in neutrophil activation in respiratory diseases... | BeFree | 24994458 | Detail |
<0.001 | Retinal Diseases | NA | BeFree | Detail | |
<0.001 | Retroviridae Infections | NA | BeFree | Detail | |
0.120 | localized scleroderma | NA | CTD_human | Detail | |
0.002 | Septicemia | Due to the severe neutropenia the patient had developed nosocomial sepsis and th... | BeFree | 25804016 | Detail |
0.003 | Septic Shock | NA | LHGDN | Detail | |
<0.001 | Sickle Cell Trait | NA | BeFree | Detail | |
0.120 | Skin Neoplasms | NA | CTD_human | Detail | |
<0.001 | smallpox | NA | BeFree | Detail | |
0.120 | Soft Tissue Neoplasms | NA | CTD_human | Detail | |
<0.001 | splenic infarction | NA | BeFree | Detail | |
0.120 | Stevens-Johnson syndrome | NA | CTD_human | Detail | |
0.120 | stomatitis | NA | CTD_human | Detail | |
0.004 | Cerebrovascular accident | NA | BeFree,LHGDN | Detail | |
<0.001 | Giant Cell Arteritis | NA | BeFree | Detail | |
<0.001 | thalassemia | NA | BeFree | Detail | |
0.120 | thrombocytopenia | NA | CTD_human | Detail | |
0.120 | Adverse reaction to drug | NA | CTD_human | Detail | |
0.120 | Uterine Neoplasms | NA | CTD_human | Detail | |
0.003 | Vascular Diseases | NA | BeFree,GAD | Detail | |
<0.001 | Albinism, Oculocutaneous | NA | BeFree | Detail | |
0.120 | B-Cell Lymphomas | NA | CTD_human | Detail | |
0.002 | diffuse large B-cell lymphoma | NA | GAD | Detail | |
0.120 | Lymphoma, AIDS-Related | NA | CTD_human | Detail | |
<0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
0.120 | Neoplasms, Second Primary | NA | CTD_human | Detail | |
<0.001 | acute leukemia | NA | BeFree | Detail | |
<0.001 | Oral Ulcer | NA | BeFree | Detail | |
0.120 | Small cell carcinoma of lung | NA | CTD_human | Detail | |
0.002 | Premature Birth | NA | GAD | Detail | |
0.120 | Muscle Weakness | NA | CTD_human | Detail | |
<0.001 | Bone pain | NA | BeFree | Detail | |
<0.001 | Primary ulcer of intestine | NA | BeFree | Detail | |
<0.001 | Idiopathic pulmonary hypertension | Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeu... | BeFree | 23933910 | Detail |
0.120 | Liver Failure, Acute | NA | CTD_human | Detail | |
<0.001 | Right Ventricular Hypertrophy | Compared with the PAH, MSC, and G-CSF groups, the HGF and HGF+G-CSF groups exhib... | BeFree | 23933910 | Detail |
0.002 | Tumor Progression | NA | BeFree | Detail | |
<0.001 | Cytomegalovirus retinitis | NA | BeFree | Detail | |
<0.001 | Cervical Intraepithelial Neoplasia | NA | BeFree | Detail | |
<0.001 | Adult Acute Myeloblastic Leukemia | NA | BeFree | Detail | |
0.001 | Cyclic neutropenia | NA | BeFree | Detail | |
<0.001 | pancreatic carcinoma | NA | BeFree | Detail | |
<0.001 | Hereditary pancreatitis | NA | BeFree | Detail | |
<0.001 | Fibrosis, Liver | NA | BeFree | Detail | |
<0.001 | Acute aortic dissection | Adventitial CXCL1/G-CSF expression in response to acute aortic dissection trigge... | BeFree | 25563839 | Detail |
0.005 | Malignant neoplasm of lung | NA | BeFree,GAD | Detail | |
0.120 | Ventricular Dysfunction, Left | NA | CTD_human | Detail | |
0.128 | Sepsis | Due to the severe neutropenia the patient had developed nosocomial sepsis and th... | BeFree,CTD_human,LHGDN | 25804016 | Detail |
<0.001 | Psoriasiform eczema | NA | BeFree | Detail | |
<0.001 | Miller Dieker syndrome | NA | BeFree | Detail | |
<0.001 | dyskeratosis congenita | NA | BeFree | Detail | |
<0.001 | Ectopic tooth | NA | BeFree | Detail | |
<0.001 | Vesicular Stomatitis | NA | BeFree | Detail | |
<0.001 | Chronic colitis | NA | BeFree | Detail | |
<0.001 | Multiple Acyl Coenzyme A Dehydrogenase Deficiency | NA | BeFree | Detail | |
<0.001 | Chronic neutrophilia | NA | BeFree | Detail | |
<0.001 | Shwachman syndrome | NA | BeFree | Detail | |
<0.001 | Myelokathexis | NA | BeFree | Detail | |
<0.001 | Carcinoma breast stage IV | NA | BeFree | Detail | |
<0.001 | Cancer of Head and Neck | NA | BeFree | Detail | |
<0.001 | secondary acute myeloid leukemia | NA | BeFree | Detail | |
<0.001 | secondary myelodysplastic syndromes | NA | BeFree | Detail | |
0.120 | Bone Marrow Neoplasms | NA | CTD_human | Detail | |
<0.001 | Restenosis | NA | BeFree | Detail | |
0.120 | Inflammatory disease of mucous membrane | NA | CTD_human | Detail | |
<0.001 | Angioendotheliomatosis | NA | BeFree | Detail | |
0.013 | Congenital neutropenia | NA | BeFree | Detail | |
<0.001 | Asymptomatic human immunodeficiency virus infection | NA | BeFree | Detail | |
<0.001 | Left ventricular dilatation | NA | BeFree | Detail | |
<0.001 | malignant mesothelioma | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of pancreas | NA | BeFree | Detail | |
<0.001 | Disseminated Malignant Neoplasm | NA | BeFree | Detail | |
<0.001 | Ischemic cardiomyopathy | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
0.002 | Hematologic Neoplasms | NA | BeFree | Detail | |
<0.001 | Prosthetic joint infection | In this study, we report that several cytokines (IL-12p40, IL-1β, TNF-α, and G-C... | BeFree | 25762781 | Detail |
<0.001 | Chromosome 8, trisomy | NA | BeFree | Detail | |
<0.001 | Ewings sarcoma | NA | BeFree | Detail | |
<0.001 | 3-Methylglutaconic aciduria type 2 | NA | BeFree | Detail | |
<0.001 | Osteosarcoma of bone | NA | BeFree | Detail | |
<0.001 | Leukemogenesis | NA | BeFree | Detail | |
<0.001 | prostate carcinoma | NA | BeFree | Detail | |
<0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
0.001 | breast carcinoma | NA | BeFree | Detail | |
<0.001 | polycythemia vera | Since the V617F mutation in JAK2 may not be the initiating event in myeloprofile... | BeFree | 19497108 | Detail |
0.002 | Carcinoma of lung | NA | BeFree | Detail | |
<0.001 | colon carcinoma | NA | BeFree | Detail | |
<0.001 | stomach carcinoma | NA | BeFree | Detail | |
0.001 | Carcinoma of bladder | NA | BeFree | Detail | |
<0.001 | skin carcinoma | NA | BeFree | Detail | |
<0.001 | Central neuroblastoma | NA | BeFree | Detail | |
<0.001 | Chronic neutropenia | NA | BeFree | Detail | |
<0.001 | Febrile Neutropenia | NA | BeFree | Detail | |
<0.001 | brain infarction | NA | BeFree | Detail | |
0.120 | Somatosensory Disorders | NA | CTD_human | Detail | |
<0.001 | Pseudomonas aeruginosa infection | NA | BeFree | Detail | |
<0.001 | Myelosuppression | NA | BeFree | Detail | |
<0.001 | Undifferentiated (Embryonal) Sarcoma | NA | BeFree | Detail | |
<0.001 | Post MI | NA | BeFree | Detail | |
<0.001 | Acute GVH disease | NA | BeFree | Detail | |
0.120 | Drug-Induced Liver Injury | NA | CTD_human | Detail | |
<0.001 | Infectious disease of lung | NA | BeFree | Detail | |
<0.001 | Cardiomyopathies | NA | BeFree | Detail | |
<0.001 | Radiculomyelopathy | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of ovary | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
<0.001 | Granulocytosis | NA | BeFree | Detail | |
<0.001 | Precursor B-cell lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | Chronic myeloproliferative disorder | G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatme... | BeFree | 25545153 | Detail |
<0.001 | Eosinophilic disorder | NA | BeFree | Detail | |
<0.001 | pericardial mesothelioma | NA | BeFree | Detail | |
<0.001 | Aplastic bone marrow | NA | BeFree | Detail | |
<0.001 | Epithelioma | NA | BeFree | Detail | |
0.120 | Mammary Neoplasms | ONO-8430506 also decreased plasma TNF-α and G-CSF cytokine levels by >70% and le... | BeFree,CTD_human | 26071407 | Detail |
<0.001 | Leukemia, Large Granular Lymphocytic | NA | BeFree | Detail | |
<0.001 | Disorder characterized by eosinophilia | NA | BeFree | Detail | |
<0.001 | Meningioma, benign, no ICD-O subtype | NA | BeFree | Detail | |
<0.001 | IMMUNE SUPPRESSION | We produced an unmanipulated haplo-HSCT protocol including granulocyte colony st... | BeFree | 25138425 | Detail |
<0.001 | lateral meningocele syndrome | The gemcitabine plus docetaxel regimen without prophylactic G-CSF support was to... | BeFree | 24149774 | Detail |
0.013 | severe congenital neutropenia | NA | BeFree | Detail | |
0.001 | Severe Aplastic Anemia | NA | BeFree | Detail | |
<0.001 | T-cell large granular lymphocyte leukemia | NA | BeFree | Detail | |
<0.001 | coronary artery disease | NA | BeFree | Detail | |
0.002 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree | Detail | |
<0.001 | liver carcinoma | NA | BeFree | Detail | |
<0.001 | Chronic idiopathic neutropenia | NA | BeFree | Detail | |
<0.001 | Extramedullary Hematopoiesis (disorder) | NA | BeFree | Detail | |
<0.001 | Steatohepatitis | Granulocyte-colony stimulating factor prevents the development of hepatic steato... | BeFree | 25671834 | Detail |
<0.001 | Promyelocytic leukemia | NA | BeFree | Detail | |
<0.001 | Severe beta thalassemia | NA | BeFree | Detail | |
0.002 | Infection of amniotic sac and membranes, unspecified, unspecified trimester, not applicable or unspecified | NA | GAD | Detail | |
0.002 | Neutropenia, severe chronic | NA | BeFree | Detail | |
<0.001 | Bone Marrow failure syndromes | NA | BeFree | Detail | |
<0.001 | myeloid neoplasm | In 2007 the WMDA responded to the publication of two manuscripts suggesting a ca... | BeFree | 25599171 | Detail |
<0.001 | Pulmonary arterial hypertension | Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeu... | BeFree | 23933910 | Detail |
<0.001 | Refractory anemia, without ringed sideroblasts, without excess blasts | NA | BeFree | Detail | |
<0.001 | Esophageal Spindle Cell Carcinoma | NA | BeFree | Detail | |
0.007 | myelodysplastic syndrome | G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatme... | BeFree,LHGDN | 25545153 | Detail |
<0.001 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | NA | BeFree | Detail | |
0.002 | Neutrophilia (disorder) | NA | BeFree | Detail | |
0.003 | Infection | NA | LHGDN | Detail | |
<0.001 | Pulmonary hypertension, primary, 1, with hereditary hemorrhagic telangiectasia | Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeu... | BeFree | 23933910 | Detail |
<0.001 | Clinical Chorioamnionitis | NA | BeFree | Detail | |
<0.001 | Acute-On-Chronic Liver Failure | NA | BeFree | Detail | |
0.120 | Spontaneous abortion | NA | CTD_human | Detail | |
<0.001 | acquired immunodeficiency syndrome | NA | BeFree | Detail | |
<0.001 | Primary myelofibrosis | NA | BeFree | Detail | |
0.121 | agranulocytosis | NA | BeFree,CTD_human | Detail | |
<0.001 | amyotrophic lateral sclerosis | NA | BeFree | Detail | |
0.121 | anemia | NA | BeFree,CTD_human | Detail | |
0.122 | aplastic anemia | NA | BeFree,CTD_human | Detail | |
<0.001 | Cooley's anemia | NA | BeFree | Detail | |
<0.001 | Refractory anemias | NA | BeFree | Detail | |
<0.001 | Refractory anaemia with excess blasts | NA | BeFree | Detail | |
<0.001 | Anemia, Sickle Cell | NA | BeFree | Detail | |
<0.001 | Aortic Rupture | Adventitial CXCL1/G-CSF expression in response to acute aortic dissection trigge... | BeFree | 25563839 | Detail |
0.120 | Arthralgia | NA | CTD_human | Detail | |
<0.001 | arthritis | NA | BeFree | Detail | |
0.003 | asthma | NA | BeFree,GAD | Detail | |
<0.001 | Astrocytoma | NA | BeFree | Detail | |
0.002 | atherosclerosis | NA | GAD | Detail | |
<0.001 | Autoimmune Diseases | NA | BeFree | Detail | |
0.002 | Bacterial Infections | Granulocyte-colony stimulating factor (G-CSF) was an effective treatment for mos... | BeFree | 25162927 | Detail |
0.002 | Bacterial Infections | Because of failure to respond to granulocyte colony-stimulating factor treatment... | BeFree | 25501410 | Detail |
<0.001 | Pneumonia, Bacterial | NA | BeFree | Detail | |
0.003 | Malignant neoplasm of urinary bladder | NA | BeFree,GAD | Detail | |
0.125 | Bladder Neoplasm | NA | CTD_human,LHGDN | Detail | |
0.001 | Malignant neoplasm of breast | NA | BeFree | Detail | |
0.002 | Bronchiolitis, Viral | NA | GAD | Detail | |
<0.001 | candidiasis | NA | BeFree | Detail | |
<0.001 | Malignant tumor of colon | NA | BeFree | Detail | |
0.120 | Non-small cell lung carcinoma | NA | BeFree,CTD_human | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These JunB-deficient mutant mice display several phenotypes from skin inflammation to a G-CSF-depend... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Granulocyte-colony stimulating factor prevents the development of hepatic steatosis in rats. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The synergistic therapeutic effect of hepatocyte growth factor and granulocyte colony-stimulating fa... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Angiogenic factors such as leptin, granulocyte colony-stimulating factor (G-CSF), follistatin, angio... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and mi... | DisGeNET | Detail |
Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granul... | DisGeNET | Detail |
Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor ... | DisGeNET | Detail |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric canc... | DisGeNET | Detail |
Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively... | DisGeNET | Detail |
Due to the severe neutropenia the patient had developed nosocomial sepsis and the dose of G-CSF was ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We hypothesized that expression of CD114, the cell surface receptor for granulocyte-colony stimulati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We aimed to assess the efficacy of vinorelbine plus granulocyte colony-stimulating factor (G-CSF) fo... | DisGeNET | Detail |
In conclusion, our data strongly indicate that G-CSF-induced CXCR2 expression is regulated in a CerS... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Increased plasma IL-6, IL-8, TNF-alpha, and G-CSF in Japanese narcolepsy. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively... | DisGeNET | Detail |
Due to the severe neutropenia the patient had developed nosocomial sepsis and the dose of G-CSF was ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, the roles of other genes, such as CSF3 (colony stimulating factor 3 receptor), CD40, TNFSF1... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
IL-8 and G-CSF play major roles in neutrophil activation in respiratory diseases. | DisGeNET | Detail |
NA | DisGeNET | Detail |
IL-8 and G-CSF play major roles in neutrophil activation in respiratory diseases. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Due to the severe neutropenia the patient had developed nosocomial sepsis and the dose of G-CSF was ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeutic benefit for the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Compared with the PAH, MSC, and G-CSF groups, the HGF and HGF+G-CSF groups exhibited significantly r... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Adventitial CXCL1/G-CSF expression in response to acute aortic dissection triggers local neutrophil ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Due to the severe neutropenia the patient had developed nosocomial sepsis and the dose of G-CSF was ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, we report that several cytokines (IL-12p40, IL-1β, TNF-α, and G-CSF) and chemokines (... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Since the V617F mutation in JAK2 may not be the initiating event in myeloprofilerative disorders (MP... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
ONO-8430506 also decreased plasma TNF-α and G-CSF cytokine levels by >70% and leukocyte infiltration... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We produced an unmanipulated haplo-HSCT protocol including granulocyte colony stimulating factor (G-... | DisGeNET | Detail |
The gemcitabine plus docetaxel regimen without prophylactic G-CSF support was tolerable and highly e... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Granulocyte-colony stimulating factor prevents the development of hepatic steatosis in rats. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In 2007 the WMDA responded to the publication of two manuscripts suggesting a causal link between G-... | DisGeNET | Detail |
Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeutic benefit for the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeutic benefit for the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Adventitial CXCL1/G-CSF expression in response to acute aortic dissection triggers local neutrophil ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Granulocyte-colony stimulating factor (G-CSF) was an effective treatment for most of the SCN patient... | DisGeNET | Detail |
Because of failure to respond to granulocyte colony-stimulating factor treatment and repeated admiss... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs386626619 dbSNP
- Genome
- hg19
- Position
- chr17:38,171,693-38,174,066
- Variant Type
- snv
Genome browser